Public Release: 

'JAKing' up blood cancers, one cell at a time

Rockefeller University Press


IMAGE: Eight months after transplantation of a single mutated cell, the bone marrow (left) and spleen (right) of a previously healthy mouse display a full-blown type of blood cancer characterized by... view more

Credit: Lundberg et al., 2014

A solitary cell containing a unique abnormality can result in certain types of blood cancers known as myeloproliferative neoplasms (MPN), according to a study published in The Journal of Experimental Medicine.

MPNs are rare types of cancer where the bone marrow makes too many cells that clog up the works and thicken the blood, potentially causing bleeding problems, heart attack, or even stroke. In 80% of MPNs, there is a mutation in a protein called JAK2, an important molecule that triggers other proteins and facilitates many cellular functions. This is one altered protein, referred to as JAK2-V617F that--among others--appears to be responsible for causing cancer cells to propagate.

By taking a single blood-generating stem cell isolated from malignant MPNs and transplanting it into healthy mice, researchers in Switzerland show that this lone cell with the mutated JAK2 protein can develop into a full-blown MPN. The resulting MPNs, in turn, also bear the JAK2 mutation. In addition, this group of scientists showed that cells in the MPNs with JAK2-V617F have the ability to renew themselves and increase their numbers.

Attempts to recapitulate this type of single-cell MPN initiation in mice have not been successful in the past. The results from this study open up exciting new opportunities to examine single JAK2-V617F mutant cells and follow tumor initiation and progression of human MPN cancers.


Lundberg, P., et al. 2014. J. Exp. Med. doi:10.1084/jem.20131371

About The Journal of Experimental Medicine

The Journal of Experimental Medicine (JEM) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JEM content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit .

Research reported in the press release was supported by the Swiss National Science Foundation and the Swiss Cancer League.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.